EMEA-000828-PIP01-09-M09
Key facts
Invented name |
Jardiance
|
Active substance |
empagliflozin
|
Therapeutic area |
Endocrinology-Gynaecology-Fertility-Metabolism
|
Decision number |
P/0283/2021
|
PIP number |
EMEA-000828-PIP01-09-M09
|
Pharmaceutical form(s) |
Film-coated tablet
|
Condition(s) / indication(s) |
Treatment of type II diabetes mellitus
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Boehringer Ingelheim International GmbH
E-mail: COMMSPaediatrics@boehringer-ingelheim.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|
Compliance procedure number |
EMEA-C-000828-PIP01-09-M09
|
Compliance opinion date |
16/12/2022
|
Compliance outcome |
positive
|